Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth

Clinical Cancer Research

Volumn 19, Issue 20, 2013, Pages 5613-5625

  Yepuru, Muralimohan ^a   Wu, Zhongzhi ^a   Kulkarni, Anand ^a   Yin, Feng ^a   M Barrett, Christina ^a   Kim, Juhyun ^a   Steiner, Mitchell S ^a   Miller, Duane D ^a   Dalton, James T ^a   Narayanan, Ramesh ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; NUCLEAR RECEPTOR COACTIVATOR; PROTEIN AKR1C3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL INTERACTION; CELL STRAIN LNCAP; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; GLEASON SCORE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TRANSACTIVATION; TUMOR GROWTH; TUMOR PROMOTION; TUMOR XENOGRAFT;

3-HYDROXYSTEROID DEHYDROGENASES; ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ENHANCER ELEMENTS, GENETIC; ENZYME INHIBITORS; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MALE; MICE; NEOPLASM STAGING; NUCLEAR RECEPTOR COACTIVATOR 2; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN BINDING; RECEPTORS, ANDROGEN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TESTOSTERONE; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84886413827     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1151     Document Type: Article

References (32)

1. Fitzpatrick JM, Anderson J, Sternberg CN, Fleshner N, Fizazi K, Rebillard X, et al. Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. Crit Rev Oncol Hematol 2008;68 Suppl 1:S9-22.
2. Higano CS, Crawford ED. New and emerging agents for the treatment of castration-resistant prostate cancer. Urol Oncol 2011;29:S1-8.
3. Shiota M, Yokomizo A, Naito S. Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol 2011;47:R25-41.
4. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
5. Yuan X, Balk SP. Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol 2009;27:36-41.
6. Labrie F. Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol 2011;8:73-85.
7. Reid AH, Attard G, Barrie E, de Bono JS. CYP17 inhibition as a hormonal strategy for prostate cancer. Nat Clin Pract Urol 2008;5: 610-20.
8. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011;71:6503-13.
9. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006;66:2815-25.
10. Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 2010;70:1256-64.
11. Brozic P, Turk S, Rizner TL, Gobec S. Inhibitors of aldo-keto reductases AKR1C1-AKR1C4. Curr Med Chem 2011;18:2554-65.
12. Bauman DR, Steckelbroeck S, Penning TM. The roles of aldo-keto reductases in steroid hormone action. Drug News Perspect 2004;17: 563-78.
13. Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol 2004;92:265-71.
14. ChangCY, McDonnell DP. Androgen receptor-cofactor interactions as targets for new drug discovery. Trends Pharmacol Sci 2005;26:225-8.
15. Narayanan R, Yepuru M, Szafran AT, Szwarc M, Bohl CE, Young NL, et al. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer. Cancer Res 2010;70:842-51.
16. Yang CH, Yue J, Fan M, Pfeffer LM. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res 2010;70:8108-16.
17. Yang CH, Yue J, Pfeffer SR, Handorf CR, Pfeffer LM. MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem 2011;286:39172-8.
18. Narayanan R, Coss CC, Yepuru M, Kearbey JD, Miller DD, Dalton JT. Steroidal androgens and nonsteroidal, tissue-selective androgen receptor modulator, S-22, regulate androgen receptor function through distinct genomic and nongenomic signaling pathways. Mol Endocrinol 2008;22:2448-65.
19. Saint-Lu N, Oortwijn BD, Pegon JN, Odouard S, Christophe OD, de Groot PG, et al. Identification of galectin-1 and galectin-3 as novel partners for von Willebrand factor. Arterioscler Thromb Vasc Biol 2012;32:894-901.
20. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006;3:995-1000.
21. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal 2008;6:e010.
22. Agoulnik IU, Vaid A, Nakka M, Alvarado M, Bingman WE III, Erdem H, et al. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res 2006;66:10594-602.
23. Qiu W, Zhou M, Labrie F, Lin SX. Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues. Mol Endocrinol 2004;18: 1798-807.
24. Byrns MC, Penning TM. Type 5 17beta-hydroxysteroid dehydrogenase/ prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact 2009;178:221-7.
25. Penning TM, Jin Y, Steckelbroeck S, Lanisnik Rizner T, Lewis M. Structure-function of human 3 alpha-hydroxysteroid dehydrogenases: genes and proteins. Mol Cell Endocrinol 2004;215:63-72.
26. Tenniswood M, Bird CE, Clark AF. The role of androgen metabolism in the control of androgen action in the rat prostate. Mol Cell Endocrinol 1982;27:89-96.
27. Saijo K, Collier JG, Li AC, Katzenellenbogen JA, Glass CK. An ADIOLERbeta-CtBP transrepression pathway negatively regulates microgliamediated inflammation. Cell 2011;145:584-95.
28. Yap TA, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:597-610.
29. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 2011;108:13728-33.
30. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, et al. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 2011;71:1486-96.
31. Mohler JL, TitusMA, Wilson EM. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res 2011;17:5844-9.
32. Desmond JC, Mountford JC, Drayson MT, Walker EA, Hewison M, Ride JP, et al. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the noncyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res 2003;63:505-12.